Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
PN6047 was also completely devoid of adverse events typically associated with conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or untoward effects following withdrawal symptoms. This validates the unique preclinical profile of PN6047, which shows that it acts very selectively on the delta opioid receptor, distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
With the Phase I trial's final report at hand and after fruitful discussions with clinical Key Opinion Leaders on designing the Phase IIa Proof of Concept study, PharmNovo is well-prepared to move PN6047 into the next stages of clinical testing.
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
PN6047 was also completely devoid of adverse events typically associated with conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or untoward effects following withdrawal symptoms. This validates the unique preclinical profile of PN6047, which shows that it acts very selectively on the delta opioid receptor, distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
With the Phase I trial's final report at hand and after fruitful discussions with clinical Key Opinion Leaders on designing the Phase IIa Proof of Concept study, PharmNovo is well-prepared to move PN6047 into the next stages of clinical testing.
Latest news
View all
17.5m EUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more